Ionis Pharmaceuticals Faces Investor Probe Following Failed Phase-3 Trial
Ionis Pharmaceuticals shares plummeted more than 20% on July 9, 2026, after the company revealed its CARDIO-TTRansform trial missed its primary endpoint. Law firm Levi & Korsinsky has launched an investigation into whether previous executive statements regarding the program’s progress misled investors about the study's risks and ultimate outcome.
The investigation centers on a potential disconnect between company guidance and the clinical reality of the Phase-3 trial, which was conducted in partnership with AstraZeneca. The study sought to measure the reduction of cardiovascular death and recurrent events in patients suffering from transthyretin-mediated amyloid cardiomyopathy.
Legal scrutiny focuses on public comments made by CEO Brett Monia leading up to the announcement. On November 6, 2024, Monia claimed the program was on track to deliver a comprehensive dataset. More recently, on June 10, 2026, he characterized the study as "reasonably derisked" and expressed optimism regarding its execution. Shareholders who incurred losses following the subsequent stock price decline are now being evaluated for potential claims regarding securities law violations.
Comments (0)
No comments yet. Be the first!